Literature DB >> 15947244

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia.

Martin Adiels1, Jan Borén, Muriel J Caslake, Philip Stewart, Aino Soro, Jukka Westerbacka, Bernt Wennberg, Sven-Olof Olofsson, Chris Packard, Marja-Riitta Taskinen.   

Abstract

OBJECTIVE: We sought to compare the synthesis and metabolism of VLDL1 and VLDL2 in patients with type 2 diabetes mellitus (DM2) and nondiabetic subjects. METHODS AND
RESULTS: We used a novel multicompartmental model to simultaneously determine the kinetics of apolipoprotein (apo) B and triglyceride (TG) in VLDL1 and VLDL2 after a bolus injection of [2H3]leucine and [2H5]glycerol and to follow the catabolism and transfer of the lipoprotein particles. Our results show that the overproduction of VLDL particles in DM2 is explained by enhanced secretion of VLDL1 apoB and TG. Direct production of VLDL2 apoB and TG was not influenced by diabetes per se. The production rates of VLDL1 apoB and TG were closely related, as were the corresponding pool sizes. VLDL1 and VLDL2 compositions did not differ in subjects with DM2 and controls, and the TG to apoB ratio of newly synthesized particles was very similar in the 2 groups. Plasma glucose, insulin, and free fatty acids together explained 55% of the variation in VLDL1 TG production rate.
CONCLUSIONS: Insulin resistance and DM2 are associated with excess hepatic production of VLDL1 particles similar in size and composition to those in nondiabetic subjects. We propose that hyperglycemia is the driving force that aggravates overproduction of VLDL1 in DM2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947244     DOI: 10.1161/01.ATV.0000172689.53992.25

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  72 in total

1.  Lipoproteins: When size really matters.

Authors:  J Bruce German; Jennifer T Smilowitz; Angela M Zivkovic
Journal:  Curr Opin Colloid Interface Sci       Date:  2006-06       Impact factor: 6.448

2.  Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.

Authors:  Ke Wu; David Cappel; Melissa Martinez; John M Stafford
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 3.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 4.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

5.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Faidon Magkos; Kevin M Korenblat; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2007-11-28       Impact factor: 22.682

Review 6.  Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.

Authors:  Hu Yan; Jin-Dong Chen; Xiao-Yan Zheng
Journal:  Psychopharmacology (Berl)       Date:  2013-07-06       Impact factor: 4.530

Review 7.  Insulin resistance and atherosclerosis.

Authors:  Babak Razani; Manu V Chakravarthy; Clay F Semenkovich
Journal:  Endocrinol Metab Clin North Am       Date:  2008-09       Impact factor: 4.741

8.  MicroRNA-management of lipoprotein homeostasis.

Authors:  Xinghui Sun; Mark W Feinberg
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

9.  Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.

Authors:  Jibiao Li; Lipeng Bi; Michelle Hulke; Tiangang Li
Journal:  J Biol Chem       Date:  2014-07-01       Impact factor: 5.157

10.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.